This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Prostate cancer	Tyrosine kinase non-receptor 2 (Tnk2; ACK1)	<p>Mouse and cell culture studies suggest inhibiting ACK1 could help reverse resistance to radiotherapy in castration-resistant prostate cancer (CRPC). In a mouse model of radiation-resistant CRPC, an inhibitor of ACK1 restored sensitivity to radiation therapy. Next steps include developing optimized ACK1 inhibitors and evaluating them in radiotherapy-resistant CRPC.</p> <p><i>SciBX</i> 5(21); doi:10.1038/scibx.2012.548 Published online May 24, 2012</p>	Unpatented; available for collaboration	<p>Mahajan, K. <i>et al.</i> <i>J. Biol. Chem.</i>; published online May 7, 2012; doi:10.1074/jbc.M112.357384 Contact: Nupam P. Mahajan, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Fla. e-mail: nupam.mahajan@moffitt.org</p>